Isto Biologics
Isto Biologics is a private, pure-play orthobiologics medical device company that develops and sells autologous concentration systems, allograft products, and synthetic bone grafts to orthopedic surgeons, physicians, and distributors for bone healing and regeneration procedures.
- Company typePrivate
- Founded1997
- HeadquartersHopkinton, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Isto Biologics does
Isto Biologics is a privately held, pure-play biologics medical device company headquartered in Hopkinton, Massachusetts, founded in 1997. The company develops and manufactures orthobiologic solutions for bone healing and regeneration, organized into three product families: autologous concentration systems (Magellan and Precise with CellectFlex technology) that process patient blood into PRP, concentrated bone marrow aspirate, and platelet poor plasma; allograft products (the Influx family — ProteiOS, Fibrant, SPARC, PLUS, Sponge — plus OsseoGen) derived from donor tissue; and synthetic bone grafts (InQu). The company targets orthopedic surgeons and physicians through an enterprise field sales model, complemented by direct rep contact systems, website quote requests, and clinical content (publications, references, patents). Revenue mechanics are device and consumable sales (hardware plus single-use kits) and allograft/synthetic product SKUs sold into surgical practices, hospitals, and through distributor partners.
The company has grown through serial M&A, acquiring Progenicare (2017), TheraCell (2022), and merging with California-based Advanced Biologics/Biologica Technologies (2023), integrating OsseoGen and ProteiOS into its allograft portfolio. Ownership transitioned from Thompson Street Capital Partners to Keensight Capital, which acquired a majority stake in October 2025. The company operates through multiple wholly-owned subsidiaries (Arteriocyte Medical Systems, Isto Technologies II, Progenicare, Progenicare Therapeutics, Advanced Transfusion Services), employs 101-250 people, and competes in the global orthobiologics market valued at $5.4B in 2021 with projected ~7% annual growth through 2026. Pricing is quote-based and not publicly disclosed; management includes Brian Barnes (CEO), Davis Adkisson (CSO), Nathan Taylor (President), and Jerry Keefe (VP Operations).
Isto Biologics firmographics
Firmographics- Name
- Isto Biologics
- Legal name
- Company, Inc.
- Website
- https://istobiologics.com
- Company type
- Private
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Isto Biologics is a private, pure-play orthobiologics medical device company that develops and sells autologous concentration systems, allograft products, and synthetic bone grafts to orthopedic surgeons, physicians, and distributors for bone healing and regeneration procedures.
- Ownership category
- akta.pro rank
Isto Biologics industry classification
Industry- Product category
- Orthobiologics & Medical Devices
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)
- akta.pro secondary industry
- Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)
Keywords
Where Isto Biologics is headquartered
LocationHeadquarters
- HQ city
- Hopkinton
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Isto Biologics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales
Revenue model
- Autologous Therapies: Sale of Magellan and Precise autologous concentration systems and associated kits for creating PRP and concentrated bone marrow aspirate therapies.
- Allograft Products: Sale of various allograft product lines including Influx, ProteiOS, Fibrant, SPARC, PLUS, Sponge, and OsseoGen derived from donor tissue for bone grafting procedures.
- Synthetic Bone Grafts: Sale of InQu biosynthetic bone graft products offering cell-friendly bone fusion solutions.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Isto Biologics product offering
Product offeringCore offering
Isto Biologics develops, manufactures, and commercializes orthobiologic medical devices and tissue-based products used in spine and orthopedic surgery. Its portfolio spans autologous point-of-care concentration systems (Magellan), bone marrow aspiration kits with proprietary CellectFlex technology (Precise line), specialty needles (Lightning Needle), and a range of allograft, synthetic, and biosynthetic bone graft substitutes (Influx line, OsseoGen, InQu) that surgeons use to support bone fusion and healing.
Differentiator
Problem solved
Functional benefit
Brands
- Magellan: Magellan Autologous Concentration System - market leading autologous concentration device for creating PRP, Concentrated Bone Marrow Aspirate, and Platelet Poor Plasma
- Precise
- Lightning Needle
- Influx
- InQu
- ProteiOS
- OsseoGen
- Precise Diamond
- Precise Sapphire
Products and services
- Magellan Autologous Concentration System
- Precise Bone Marrow Aspiration Kit
- Lightning Needle
- Influx Product Line
- OsseoGen
- InQu Biosynthetic Bone Graft
Quantifiable outcome
- InQu biosynthetic bone graft outperforms fusion rates of ICBG (Iliac Crest Bone Graft)
- +1 more outcomes
Companies that use Isto Biologics
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles2 records
Isto Biologics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Isto Biologics partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and minor.
- Advanced BiologicscoreAdvanced Biologics, also known as Biologica Technologies, merged with Isto Biologics in October 2023. The merger integrated Advanced Biologics' proprietary products including OsseoGen and ProteiOS into Isto's portfolio, combining clinical, research, and commercial expertise.
- TheraCellminorIsto Biologics acquired TheraCell to expand its regenerative therapy capabilities. TheraCell was integrated into Isto's biologics portfolio.
Scale indicators3 records
Recent moves5 records
Expansion highlights5 records
Isto Biologics competitors and assessment
Company assessmentDirect peers
- Arthrex: A privately held, large orthopedics and sports medicine company with a broad orthobiologics portfolio including allografts, PRP systems, and bone graft substitutes. Arthrex competes directly with Isto in surgeon-targeted biologics for orthopedic and sports medicine procedures.
- Globus Medical: Spine-focused medical device company with a growing orthobiologics portfolio including bone graft substitutes and regenerative products. Directly comparable to Isto in the spine biologics segment and now combined with NuVasive.
- Orthofix Medical: Spine and orthopedics company with a dedicated biologics portfolio including bone graft solutions and regenerative products. Comparable to Isto as a focused player in orthobiologics with overlapping surgeon call points.
- Bioventus: Pureplay orthobiologics company offering bone graft substitutes, hyaluronic acid injections, and regenerative therapies. Directly comparable to Isto as a focused biologics competitor in bone healing and joint preservation.
- SeaSpine: Spine-focused medical device company with a meaningful orthobiologics portfolio including allograft and synthetic bone graft substitutes. Comparable to Isto in spinal fusion and orthopedic biologics markets.
- MTF Biologics: Non-profit tissue bank and orthobiologics manufacturer with a broad portfolio of allograft products for bone, cartilage, and soft tissue repair. Comparable to Isto as a tissue-derived biologics supplier serving orthopedic surgeons.
Broad incumbents
- Medtronic: Global medical device leader with a significant spine and biologics franchise, including the Infuse bone graft (rhBMP-2) product. Medtronic competes with Isto in spinal fusion biologics and broader orthobiologic applications as part of a much wider implant portfolio.
- Stryker: Major orthopedic medtech company offering bone graft substitutes, allografts, and regenerative products within its orthopedics and spine portfolio. Competes with Isto across multiple biologics categories and has substantially greater scale and sales reach.
- DePuy Synthes (Johnson & Johnson MedTech): Orthopedics and spine franchise of J&J MedTech offering bone grafts and regenerative solutions as part of a comprehensive orthopedic portfolio. Competes with Isto in trauma, spine, and reconstructive orthobiologics markets.
- Zimmer Biomet: Global orthopedic device manufacturer with a biologics portfolio spanning bone grafts and regenerative products. Competes with Isto across orthopedic reconstructive, sports medicine, and trauma biologics.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Isto Biologics social profiles
Digital presenceIsto Biologics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Isto Biologics leadership team
Management profileNumber of profiles
Profiles4 records
Isto Biologics subsidiaries and ownership
Company hierarchySubsidiaries5 records
Isto Biologics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Isto Biologics M&A and investment
M&A and investmentM&A3 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Isto Biologics
What does Isto Biologics do?
Isto Biologics develops, manufactures, and commercializes orthobiologic medical devices and tissue-based products used in spine and orthopedic surgery. Its portfolio spans autologous point-of-care concentration systems (Magellan), bone marrow aspiration kits with proprietary CellectFlex technology (Precise line), specialty needles (Lightning Needle), and a range of allograft, synthetic, and biosynthetic bone graft substitutes (Influx line, OsseoGen, InQu) that surgeons use to support bone fusion and healing.
Is Isto Biologics a public or private company?
Isto Biologics is a private company. It is classified as private equity controlled and is currently operating.
When was Isto Biologics founded?
Isto Biologics was founded in 1997. It employs 101 to 250 people.
Where is Isto Biologics based?
Isto Biologics is headquartered in Hopkinton, United States, in the North America region.
How does Isto Biologics make money?
Three revenue lines are on record. Autologous Therapies are the primary driver. The others are allograft Products and synthetic Bone Grafts.
Who are Isto Biologics's main competitors?
Direct peers on record are Arthrex, Globus Medical, Orthofix Medical, Bioventus, SeaSpine and MTF Biologics. Broad incumbents are Medtronic, Stryker, DePuy Synthes (Johnson & Johnson MedTech) and Zimmer Biomet.
Does Isto Biologics have an API?
No public API is recorded for Isto Biologics.
What industry is Isto Biologics in?
Isto Biologics's product category is Orthobiologics & Medical Devices. Its primary akta.pro industry code is HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM), with a secondary code of HLAAAGAH, Cartilage, Bone & Musculoskeletal Regeneration. Its NAICS code is 339113 and its SIC code is 3842.